

Sunil Suresh & Associates

CHARTERED ACCOUNTANTS

Off. : 0129-4030308
0129-4105000

CA Sunil K. Garg : 9811015509

Adv. Sanjay Goyal : 9312020811

CA Vinay Sharma : 9990407498

Off. : B-20/21, Ground Floor,
Fruit Garden, N.I.T.
Faridabad-121001
E-mail : cargs45@gmail.com

Review Report

To
The Board of Directors
Kimia Biosciences Limited
Village Bhondsi, Tehsil Sohna
Gurgaon Haryana-122102

1. We have reviewed the accompanying statement of unaudited financial results of Kimia Biosciences Limited (the "Company") for the quarter ended September 30, 2024 (the "Statement") and year to date results for the period from April 01, 2024 to September 30, 2024, being submitted by the company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulation, 2015"), which has been initialled by us for identification purposes. The statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement.
3. Review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in accordance with applicable accounting standards prescribed under Section 133 of the Companies Act 2013 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Sunil Suresh & Associates
FRN 011646N

Neeraj Kumar Arora
Partner



M. No. 510750
UDIN:- 24510750 BKFDUI 4379
Place:- Gurugram
Dated:- November 14, 2024

KIMIA BIOSCIENCES LIMITED

Regd. Office : Village Bhondsi, Tehsil Sohna, Dist. Gurgaon , Haryana - 122102

Phone: +91 9654746544, 9654206544 Email: compliance.kimia@gmail.com & info@kimiabiosciences.com

Website: www.kimiabiosciences.com, CIN : L24239HR1993PLC032120

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2024


(₹ Lakhs except EPS)

S. No.	Particulars	Quarter ended			Half Year Ended		Year Ended
		30/09/2024	30/06/2024	30/09/2023	30/09/2024	30/09/2024	31/03/2024
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I	Revenue from Operations	2,817.86	2,239.93	2,420.01	5,057.79	4,843.02	10,487.65
II	Other Income	37.09	8.33	63.74	45.42	76.26	164.18
III	Total Income (I+II)	2,854.95	2,248.26	2,483.75	5,103.21	4,919.28	10,651.83
IV	Expenses:						
	a) Cost of materials consumed	1,746.35	1,497.22	970.43	3,243.57	2,861.35	6,735.80
	b) Change in inventories of finished goods and work-in-progress	(20.95)	(274.57)	872.75	(295.52)	771.08	789.73
	c) Employee benefits expenses	352.45	342.83	389.52	695.28	788.22	1,515.25
	d) Finance costs	103.93	110.84	111.92	214.77	239.50	504.98
	e) Depreciation and amortisation expense	78.64	89.78	82.31	168.42	165.52	329.23
	f) Other expenses	403.10	303.96	383.47	707.06	782.42	1,495.21
V	Total Expenses (IV)	2,663.52	2,070.06	2,810.40	4,733.58	5,608.09	11,370.20
VI	Profit/(loss) before exceptional items and Tax (III-V)	191.43	178.20	(326.65)	369.63	(688.81)	(718.37)
VII	Exceptional Items	-	-	-	-	-	-
VI	Profit/(loss) before tax (IV-V)	191.43	178.20	(326.65)	369.63	(688.81)	(718.37)
VII	Tax expenses:						
	a) Current Tax	31.95	29.74	-	61.69	-	-
	b) Deferred Tax charge / (credit)	(1.86)	4.75	(82.48)	2.90	(173.59)	(187.50)
VIII	Profit/(loss) for the period (VI-VII)	161.34	143.70	(244.17)	305.04	(515.22)	(530.87)
IX	Other Comprehensive Income						
A.	Items that will not be reclassified to Profit or Loss (Net of Tax)						
	- Remeasurement of defined benefit plans	-	-	-	-	-	17.69
B.	Items that will be reclassified to Profit or Loss (Net of Tax)						
X	Total Comprehensive Income for the period (VIII+IX)	161.34	143.70	(244.17)	305.04	(515.22)	(513.18)
XI	Paid up equity share capital (Face value of Rs.1 per equity share)	473.13	473.13	473.13	473.13	473.13	473.13
XII	Other Equity						(440.03)
XIII	Earnings per equity share (not annualised)						
	Basic in Rs.	0.34	0.30	(0.52)	0.64	(1.09)	(1.12)
	Diluted in Rs.	0.34	0.30	(0.52)	0.64	(1.09)	(1.12)

STATEMENT OF ASSETS, EQUITY and LIABILITIES




S. No.	Particulars	As at 30-09-2024 (Unaudited)	As at 31-03-2024 (Audited)
A	ASSETS		
1	Non-Current Assets		
	Property, Plant & Equipment	3,047.04	3,149.95
	Capital Work-in-Progress	-	57.62
	Right of Use Assets	54.23	30.46
	Other Intangible Assets	2.58	4.09
	Deferred Tax Assets (Net)	575.53	578.43
	Financial Assets		
	(i) Other Non Current Financial Assets	36.30	26.32
	Other Non-current Assets	-	9.03
2	Current Assets		
	Inventories	3,367.92	3,080.35
	Financial Assets		
	(i) Investment	-	-
	(ii) Trade Receivables	2,496.38	2,755.40
	(iii) Cash and Cash Equivalents	33.22	14.76
	(iv) Bank balances other than (iii) above	44.37	38.68
	(v) Other Current Financial Assets	140.51	103.12
	Current Tax Assets (Net)	70.40	73.11
	Other Current Assets	23.67	75.33
	Total Assets	9,892.15	9,996.66
B	EQUITY & LIABILITIES		
1	EQUITY		
	(a) Share Capital	473.13	473.13
	(b) Other Equity	(134.99)	(440.03)
2	NON CURRENT LIABILITIES		
	Financial Liabilities		
	(i) Borrowings	1,807.43	2,140.98
	(ii) Lease Liabilities	40.99	18.45
	(iii) Other financial liabilities	606.84	580.71
	Provisions	160.45	144.90
	Other Non-Current Liabilities	109.75	134.75
3	CURRENT LIABILITIES		
	Financial Liabilities		
	(i) Borrowings	2,006.37	2,199.15
	(ii) Lease Liabilities	15.26	12.13
	(iii) Trade Payables		
	a. Total Outstanding due to Micro and Small Enterprises	4.73	4.95
	b. Total Outstanding due to other than Micro and Small Enterprises	3,824.63	3,993.87
	(iii) Other Financial Liabilities	519.25	506.63
	Other Current Liabilities	396.61	224.39
	Provisions	61.69	2.65
	Total Equity and Liabilities	9,892.15	9,996.66

KIMIA BIOSCIENCES LIMITED

Regd. Office : Village Bhondsli, Tehsil Sohna, Dist. Gurgaon, Haryana - 122102

Phone: +91 9654746544, 9654206544 Email: compliance.kimia@gmail.com & info@kimiabiosciences.com

Website: www.kimiabiosciences.com, CIN : L24239HR1993PLC032120

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2024



STATEMENT OF CASH FLOWS

Particulars	For the half year ended 30-09-2024 (Unaudited)	For the half year ended 30-09-2023 (Unaudited)
A. Cash Flow from Operating Activities		
Net Profit / (Loss) before tax	369.63	(688.91)
Adjustment for :		
Depreciation and amortization expense	168.42	165.52
Finance costs	214.77	239.50
Gain on fair value of investment in mutual funds	-	(0.02)
Interest income	-	(1.08)
Deferred revenue income	(0.68)	(25.00)
Unrealised (gain)/loss on foreign currency transactions and translations	-	(9.61)
Operating Profit Before Working Capital Changes	752.14	(319.50)
Adjustments for:		

Amun Jain




(Increase) / Decrease in inventories	(287.57)	1,163.58
(Increase) / Decrease in trade and other receivables	275.05	875.90
Increase / (Decrease) in trade and other payables	139.56	(1,394.71)
Cash Generated From Operations	879.18	325.27
Less : Income tax paid / (refunds)	2.71	(1.76)
Net Cash From Operating Activities	881.89	323.51
B. Cash Flow from Investment Activities		
Purchases of property, plant and equipments including intangible assets & capital advances	(95.03)	(56.60)
Net inflow / (outflow) in fixed deposits	(5.69)	(5.00)
Purchase of current investments	-	-
Interest received	0.68	-
Net Cash Used In Investing Activities	(100.04)	(61.60)
C. Cash Flow from Financing Activities		
Receipts from non current borrowings	-	-
Repayment of non current borrowings	(333.55)	(50.69)
Net proceeds of current borrowings	(192.78)	(61.57)
Finance costs paid	(237.72)	(152.66)
Net Cash Used in Financing Activities	(764.05)	(264.92)
Net Increase / (Decrease) in Cash and Cash Equivalents	17.81	(3.00)
Cash and Cash Equivalents at the beginning of the period	18.46	17.77
Cash and Cash Equivalents at the end of the period	33.22	21.11

Other Notes

1 The business activity of the Company falls within a single primary business segment viz 'Pharmaceuticals' and hence there is no other reportable segment as per Ind AS 108 'operating segments'.

Date: November 14, 2024
Place: New Delhi

FOR KIMIA BIOSCIENCES LIMITED



Sameer Goel
(Managing Director & CEO)
DIN - 00161786